Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time-of-Day of Immunochemotherapy in Advanced NSCLC
NCT05549037Phase 3Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab and sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival at 36 months. Started Sep 2022; status: completed.
02
Drugs
pembrolizumabsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05549037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549037.